SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
17th Jun 202111:29 amRNSDirector/PDMR Shareholding
16th Jun 20212:13 pmRNSAdditional Listing
2nd Jun 202111:10 amRNSDirector/PDMR Shareholding
1st Jun 20219:35 amRNSBlock listing Interim Review
28th May 20211:09 pmRNSTotal Voting Rights
18th May 20214:50 pmRNSDirector Declaration
18th May 202110:32 amRNSDirector/PDMR Shareholding
17th May 202110:56 amRNSDirector/PDMR Shareholding
13th May 202110:08 amRNSAdditional Listing
10th May 20217:00 amRNSVictrex plc Interim Results
30th Apr 20212:41 pmRNSTotal Voting Rights
19th Apr 20212:37 pmRNSDirector/PDMR Shareholding
16th Apr 202110:36 amRNSDirector Declaration
9th Apr 202111:00 amRNSAdditional Listing
31st Mar 20211:52 pmRNSTotal Voting Rights
17th Mar 20211:41 pmRNSDirector/PDMR Shareholding
1st Mar 202111:37 amRNSDirector/PDMR Shareholding
26th Feb 20211:47 pmRNSTotal Voting Rights
17th Feb 202110:32 amRNSDirector/PDMR Shareholding
12th Feb 20211:53 pmRNSResult of AGM
12th Feb 20217:00 amRNSAGM and Q1 Interim Management Statement
10th Feb 20212:37 pmRNSDirector/PDMR Shareholding
29th Jan 20212:33 pmRNSTotal Voting Rights
19th Jan 20213:50 pmRNSDirector/PDMR Shareholding
7th Jan 20212:06 pmRNSAnnual Report and Accounts
6th Jan 20212:34 pmRNSDirector/PDMR Shareholding
31st Dec 20209:00 amRNSTotal Voting Rights
17th Dec 20203:09 pmRNSDirector/PDMR Shareholding
15th Dec 202012:57 pmRNSDirector/PDMR Shareholding
11th Dec 20202:47 pmRNSDirector/PDMR Shareholding
9th Dec 20207:00 amRNSVictrex plc – Preliminary Results 2020
1st Dec 202010:59 amRNSBlock listing Interim Review
30th Nov 202011:24 amRNSTotal Voting Rights
17th Nov 20209:49 amRNSDirector/PDMR Shareholding
30th Oct 202011:40 amRNSTotal Voting Rights
19th Oct 202011:34 amRNSDirector/PDMR Shareholding
14th Oct 202012:17 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSVictrex plc Full Year Trading Statement
30th Sep 20209:30 amRNSTotal Voting Rights
29th Sep 20204:09 pmRNSHolding(s) in Company
17th Sep 202011:00 amRNSDirector/PDMR Shareholding
28th Aug 20209:56 amRNSTotal Voting Rights
19th Aug 202011:01 amRNSDirector/PDMR Shareholding
31st Jul 202011:53 amRNSTotal Voting Rights
20th Jul 202010:45 amRNSDirector/PDMR Shareholding
17th Jul 20204:43 pmRNSDirector/PDMR Shareholding
8th Jul 20207:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202011:30 amRNSTotal Voting Rights
17th Jun 202011:44 amRNSDirector/PDMR Shareholding
15th Jun 20204:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.